The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Immunotherapeutic options for patients with MCL who progress on BTK inhibitors
Jonathon Cohen, MD, MS, Emory University School of Medicine, Atlanta, GA, discusses immunotherapeutic options for patients with mantle cell lymphoma (MCL) who relapse or progress on Bruton’s tyrosine kinase (BTK) inhibitors. Dr Cohen first explains the promise of CAR-T cells, including brexucabtagene autoleucel, and then goes on to highlight the potential role of antibodies, antibody-drug conjugates (ADCs), and bispecifics. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
